PORTLAND, Maine–(BUSINESS WIRE)–MedRhythms, a leader in developing prescription digital therapeutics that use sensors, software, and music to measure and improve walking for patients with a neurologic injury or disease, today announced the closing of a Series B extension round, with investment from one of Japan’s largest venture capital companies Global Brain with its CVC JGC MIRAI Innovation Fund, and Bose Ventures. The follow-on investment brings the Company’s total Series B financing to $27 million, an increase from their announcement in July. Read more
Related Posts
Maine’s life sciences sector growth could outpace other industries
Maine’s $2.3 billion life sciences sector, which employed close to 10,000 people in 2024, will outpace the growth of many other...
IDEXX gets wiggle room to buy back more shares
IDEXX Laboratories Inc. (Nasdaq: IDXX), a Westbrook-based maker of veterinary diagnostics and software, has the green light from its board of...
Maine’s first accredited lab for PFAS testing is expanding to meet demand
NORRIDGEWOCK, Maine — This week, the Biden administration moved to prevent dangerous “forever chemicals” from being released onto the market after a less...